Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/11/2025

Rituximab Administration Guidelines

Pre-Treatment Evaluation

  • Patients should undergo checking of immunoglobulin levels (IgG, IgM, IgA) before rituximab administration, as recommended by the American College of Physicians and the Mayo Clinic Proceedings 1
  • Serum IgM levels should be evaluated in patients with Waldenström's macroglobulinemia, especially if >4000 mg/dL, due to the risk of hyperviscosity syndrome, as reported in Blood 2
  • A tuberculin skin test or interferon-gamma release assay should be performed before rituximab administration, as recommended by the Mayo Clinic Proceedings 1

Vaccination and Infection Prevention

  • Live attenuated vaccines are contraindicated in immunosuppressed patients, as stated by the European League Against Rheumatism and published in the Annals of the Rheumatic Diseases 3
  • Annual influenza vaccination with quadrivalent vaccine is recommended for patients receiving rituximab therapy, as suggested by the European League Against Rheumatism and European Society for Medical Oncology 4, 5, 6
  • Pneumococcal vaccination with 13-valent conjugate vaccine (PCV13) followed by polysaccharide vaccine (PPSV23) 8-12 weeks later is recommended for patients receiving rituximab therapy, as suggested by the European League Against Rheumatism and European Society for Medical Oncology 4, 6
  • Other recommended vaccinations for patients receiving rituximab therapy include:
  • All vaccinations should be completed at least 4 weeks before starting rituximab therapy, as recommended by the European League Against Rheumatism and American College of Rheumatology 4, 5, 3
  • If rituximab therapy has already begun, vaccinations should be administered at least 6 months after the last rituximab dose and 4 weeks before the next dose, as recommended by the European League Against Rheumatism 4
  • In the case of influenza vaccination, the next rituximab dose should be delayed by at least 2 weeks, as recommended by the European League Against Rheumatism and American College of Rheumatology 4, 5
  • Other inactivated vaccines should be administered shortly before the next planned rituximab dose, and rituximab should be withheld for at least 2 weeks, as recommended by the American College of Rheumatology 5
  • Live vaccines should be avoided in immunosuppressed patients, such as those receiving rituximab therapy (e.g., yellow fever vaccine), as recommended by the European League Against Rheumatism 4
  • Tetanus immunoglobulin should be administered in cases of contaminated wounds if rituximab was given within the last 6 months, as recommended by the European League Against Rheumatism 4, 3
  • Family members should be screened for their vaccination status, and rotavirus vaccination is not recommended for young children in the household, as suggested by the European Society for Medical Oncology 6

Treatment Considerations

  • Prophylactic plasmapheresis should be considered before rituximab administration in patients with Waldenström's macroglobulinemia and high IgM levels (≥4000 mg/dL) to prevent hyperviscosity complications, as suggested in Blood 2
  • Late-onset neutropenia can occur with rituximab, especially when combined with chemotherapy, as reported in Blood 2
  • The immune response to vaccinations is severely impaired for up to 6 months after rituximab administration, as reported by the European League Against Rheumatism and American College of Rheumatology 7, 5, 3
  • Optimal immune response to vaccinations is expected more than 9 months after the last rituximab dose, although the exact timing may vary, as reported by the European League Against Rheumatism and American College of Rheumatology 7, 5, 3
  • Combination of rituximab with other immunosuppressive medications can further reduce immune response to vaccinations, as reported by the European League Against Rheumatism 7
  • HBV reactivation can occur up to 1-2 years after rituximab discontinuation, and fatal consequences can include fulminant hepatitis, liver failure, and death, as reported by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver 8, 9

Hepatitis B Screening and Prophylaxis

  • Patients should be screened for hepatitis B virus (HBV) infection, HIV, hepatitis C virus (HCV) antibody, and tuberculosis before starting rituximab therapy, as recommended by the American Gastroenterological Association and European League Against Rheumatism 8, 10
  • Baseline HBV DNA is recommended for patients with positive HBsAg or anti-HBc, as suggested by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver 8
  • Antiviral prophylaxis with entecavir or tenofovir is recommended for patients with positive HBsAg or anti-HBc before starting rituximab therapy, as suggested by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver 8, 11
  • Prophylaxis should begin 2-4 weeks before rituximab when possible and continue for at least 12-18 months after completing rituximab therapy, as suggested by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver 8, 11
  • Monitor HBsAg and HBV DNA for at least 12 months after prophylaxis withdrawal, as suggested by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver 8
  • Consultation with a hepatologist is recommended for all HBsAg or anti-HBc positive patients prior to rituximab initiation, as suggested by the American Society of Nephrology 9

REFERENCES